Michael Heffernan
Board Chair
Michael Heffernan brings to the Par Health Board more than 30 years of entrepreneurial leadership, operational expertise in biopharmaceuticals and healthcare, and a proven record of guiding companies through commercialization and strategic transactions.
Mr. Heffernan was the Founder and Chairman of Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on developing and commercializing medicines for pain management. He previously served as Collegium’s President and CEO.
He has successfully built and led multiple companies through growth, commercialization, and strategic transactions, including Onset Dermatologics, which he founded and later spun out of Collegium to create PreCision Dermatology, Inc., subsequently sold to Valeant. Earlier in his career, Mr. Heffernan co-founded and served as CEO of Clinical Studies Ltd., a pharmaceutical contract research organization acquired by PhyMatrix Corp., where he later became CEO and Chairman.
In addition to his executive roles, Mr. Heffernan has served as an advisor, investor, and board member for numerous biopharma, medical device, and healthcare services companies.
Mr. Heffernan holds a Bachelor of Science in Pharmacy from the University of Connecticut and is a registered pharmacist.